Efgartigimod Builds a Pediatric Track Record in Myasthenia Gravis

from TheBrief.Health · host TheBrief.Health

At AAN Annual Meeting 2026, efgartigimod alfa showed durable adolescent gMG responses, with 80% achieving minimal symptom expression by cycle two and consistent improvements across treatment cycles.

Episode metadata supplied by the publisher feed · Published Apr 30, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

Efgartigimod Builds a Pediatric Track Record in Myasthenia Gravis

0:00 1:21

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of TheBrief.Health?

This episode is 1 minute long.

When was this TheBrief.Health episode published?

This episode was published on April 30, 2026.

Can I download this TheBrief.Health episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!